High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom

Neil F. Moran*, William J. Newman, R. David G Theakston, David A. Warrell, David Wilkinson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)


During a prospective study of 147 patients with snakebite presenting to a rural South African hospital, 13 of 17 patients (76%) treated with South African Institute for Medical Research (SAIMR) polyvalent antivenom experienced potentially severe early (anaphylactoid) reactions. The most common reaction was generalized urticaria (12; 71%), but 3 cases of angio-oedema (18%), 2 of bronchospasm (12%), and 2 of hypotension (12%) were also observed. Reactions were controlled with adrenaline, antihistamines, and resuscitation. All patients fully recovered from envenoming although the full dose of antivenom was not given to most. Indications for the use of this antivenom should be reconsidered and patients should be given antivenom in a high care setting if possible. Use of antivenom by lay people outside hospital should be discouraged and antivenom manufacturing processes could usefully be reviewed.

Original languageEnglish
Pages (from-to)69-70
Number of pages2
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Issue number1
Publication statusPublished - 1998
Externally publishedYes


  • Anaphylactoid reaction
  • Antivenom
  • Snakebite
  • South Africa


Dive into the research topics of 'High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom'. Together they form a unique fingerprint.

Cite this